Advertisement

Topics

Companies Related to "A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolearbility in Non-ambulant DMD Subjects" [Most Relevant Company Matches] RSS

19:46 EDT 21st August 2018 | BioPortfolio

Here are the most relevant search results for "A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolearbility in Non-ambulant DMD Subjects" found in our extensive corporate database of over 50,000 company records.

Showing "Double blind Escalating Dose Randomized Placebo controlled Study" Companies 1–25 of 1,100+

Extremely Relevant

Adeona Pharmaceuticals, Inc.

Adeona (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration. Trimesta (estriol) ...


Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...

Agennix

Agennix is a privately held biotechnology company whose lead molecule, Talactoferrin Alfa (talactoferrin; TLF), is an immunomodulatory protein. Agennix is currently preparing to initiate Phase III development of oral talactoferrin for cancer, and topical talactoferrin gel for wound healing.Liquid talactoferrin is an oral anti-cancer drug that has shown activity both as monotherapy and in combinati...


DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a comm...

Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development ...

Celleration, Inc.

Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology delivers non-contact, low-frequency, low-intensity ultrasound to the patient's injured soft tissue in a painless fashion. The chronic diabetic foot ulcer market had been the Company's initial focus. MIST Therapy(R) has since ...

Relevant

Favrille

We are a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. We own a proprietary technology that enables us to efficiently develop and manufacture active immunotherapy products designed to stimulate a patient's own immune system to mount a specific and sustained response...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Privia

A clinical trial is a research study. Research studies are used to decide how treatments work and how safe they are. While in a study, a person may receive either an investigational drug, a marketed drug, a placebo, or a combination of these. An investigational drug is one that is nor approved by the Food and Drug Administration, a marketed drug is FDA approved and a placebo is like a "sugar pill"...

National Federation of the Blind (NFB)

With more than 50,000 members, the National Federation of the Blind is the largest and most influential membership organization of blind people in the United States. The NFB improves blind people’s lives through advocacy, education, research, technology, and programs encouraging independence and self-confidence. It is the leading force in the blindnes...

Cypress Bioscience

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications....

National Federation of the Blind

With more than 50,000 members, the National Federation of the Blind is the largest and most influential membership organization of blind people in the United States. The NFB improves blind people's lives through advocacy, education, research, technology, and programs encouraging independence and self-confidence. It is the leading force in the blindness field today and the voice of the nation's b...

LifeWave Ltd

Incorporated in 2000, LifeWave Ltd. is a premier provider of innovative medical device in the field of Advanced Wound Management. The Company has developed an extensively researched and clinically-validated product that represents a truly novel approach in addressing the critical medical issue of chronic wounds care. LifeWave is currently focused on introducing its product to global markets. Chron...

Ameritox

The single-group, multi-dose study examined the ability of the Rx Guardian(SM) algorithm to differentiate among low, medium and high daily doses of OxyContin®. Oxycodone levels were detected in the urine of 36 healthy volunteers using a liquid chromatography-mass spectrometry (LC-MS-MS) assay. Participants were randomized to receive 80mg, 160mg or 240mg of daily OxyContin® to steady state cond...

National Federation of the Blind of Michigan

The National Federation of the Blind of Michigan is the state’s oldest and largest organization of blind consumers. Founded in 1941, we have chapters in most large cities in Michigan and provide advocacy, information about blindness, scholarships, and many other services that work toward our goal to change what it means to be blind in Michigan.

European Randomized Study of Screening for Prostate Cancer (ERSPC)

ERSPC (European Randomized Study of Screening for Prostate Cancer)

Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...

Nutrition 21

Leveraging its biotechnology heritage, Nutrition 21 is pioneering an effort to use patented technology, pharmaceutical research and strategic marketing and distribution partnerships to build its position in therapeutic markets. The Company is targeting specific disease states and age related health care concerns through its Chromax®, Diachrome®, Iceland Health®, and Selenomax® brands. The dis...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...


More From BioPortfolio on "A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolearbility in Non-ambulant DMD Subjects"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks